

Date: 9<sup>th</sup> December, 2022

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.  
'Exchange Plaza', Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

Dear Sir/Madam,

**Sub: Alembic Pharmaceuticals Limited receives Establishment Inspection Report (EIR) for its Oncology Injectable Formulation Facility at Panelav**

**Ref.: Our earlier intimation dated 17<sup>th</sup> October, 2022 - USFDA inspection at Alembic Pharmaceuticals' Oncology Injectable Formulation Facility at Panelav**

This is to inform the exchange that the Company has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out by them at our Oncology Injectable Formulation Facility at Panelav during the period from 4<sup>th</sup> October, 2022 to 14<sup>th</sup> October, 2022. This was pre-approval inspection to cover our Oncology Injectable drug products for which ANDAs were filed with USFDA. The Company had also started receiving ANDA approval manufactured at this facility.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Alembic Pharmaceuticals Limited**

**Charandeep Singh Saluja**  
**Company Secretary**

**ALEMBIC PHARMACEUTICALS LIMITED**